These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25999432)

  • 1. Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy.
    Fahey F; Zukotynski K; Jadvar H; Capala J;
    J Nucl Med; 2015 Jul; 56(7):1119-29. PubMed ID: 25999432
    [No Abstract]   [Full Text] [Related]  

  • 2. Joint NCI/SNMMI workshop on targeted radionuclide therapy.
    J Nucl Med; 2015 Jan; 56(1):13N. PubMed ID: 25556227
    [No Abstract]   [Full Text] [Related]  

  • 3. Joint NCI/SNMMI Workshop on Targeted Radionuclide Therapy.
    J Nucl Med; 2013 May; 54(5):16N-7. PubMed ID: 23757490
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging.
    Fahey F; Zukotynski K; Capala J; Knight N;
    J Nucl Med; 2014 Feb; 55(2):337-48. PubMed ID: 24396032
    [No Abstract]   [Full Text] [Related]  

  • 5. EANM Focus 1: one small step for two men, one giant leap for a specialty.
    Fanti S; Oyen WJG
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1400-1401. PubMed ID: 31016331
    [No Abstract]   [Full Text] [Related]  

  • 6. SNMMI leadership update: reaching out to develop a unified voice.
    Herscovitch P
    J Nucl Med; 2015 Mar; 56(3):16N. PubMed ID: 25733604
    [No Abstract]   [Full Text] [Related]  

  • 7. Perspective: multimodality radionuclide therapy of progressive disseminated lymphoma and neuroendocrine tumors as a paradigm for cancer control.
    Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):525-9. PubMed ID: 23062194
    [No Abstract]   [Full Text] [Related]  

  • 8. From the magic bullet to an effective therapy: the peptide experience.
    Mansi L
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1393-8. PubMed ID: 15351914
    [No Abstract]   [Full Text] [Related]  

  • 9. Somatostatin imaging of neuroendocrine-differentiated prostate cancer.
    Hope TA; Aggarwal R; Simko JP; VanBrocklin HF; Ryan CJ
    Clin Nucl Med; 2015 Jun; 40(6):540-1. PubMed ID: 25783510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging news from NCI and the Cancer Imaging Program.
    Croft BY
    J Nucl Med; 2009 Mar; 50(3):15N. PubMed ID: 19258252
    [No Abstract]   [Full Text] [Related]  

  • 11. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours.
    Forrer F; Mueller-Brand J; Maecke H
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):511-2; author reply 513. PubMed ID: 15688195
    [No Abstract]   [Full Text] [Related]  

  • 12. Dosimetry in Peptide radionuclide receptor therapy: a review.
    Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
    J Nucl Med; 2006 Sep; 47(9):1467-75. PubMed ID: 16954555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
    Jadvar H
    AJR Am J Roentgenol; 2017 Aug; 209(2):277-288. PubMed ID: 28463538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force.
    Prior JO; Gillessen S; Wirth M; Dale W; Aapro M; Oyen WJG
    Eur J Cancer; 2017 May; 77():127-139. PubMed ID: 28391026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; de Herder WW; Krenning EP
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides.
    Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):288-95. PubMed ID: 17043626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
    Timmermand OV; Tran TA; Strand SE; Axelsson J
    J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiopharmacology: recent developments in the field of radiopharmaceuticals.
    Cutler CS
    Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):239-40. PubMed ID: 26404758
    [No Abstract]   [Full Text] [Related]  

  • 19. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
    Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
    Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National Cancer Institute Programmatic Collaboration for Investigational Radiopharmaceuticals.
    Kunos CA; Capala J
    Am Soc Clin Oncol Educ Book; 2018 May; 38():488-494. PubMed ID: 30231365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.